Blog

Bubble risk for AI start-ups in the healthcare sector A regulatory leap imposing high costs, the accrual of obligations and the difficulties of moving from pilot projects to commercialisation are the determining factors by Monica D'AscenzoThe healthcare technology sector is at a turning point, which could mark the bursting of a financial bubble. After a two-year period between 2024 and 2025 characterised by unprecedented capital inflows and booming valuations, the market would be heading for a structural correction in 2026.The fear of a 'bursting' of the artificial intelligence bubble applied to healthcare is not attributable to a simple negative venture capital cycle, but appears to be the mathematical outcome of three converging forces, according to analysts at Nelson Advisors: 'an abrupt regulatory jump imposing typical hardware compliance costs on software start-ups, the maturation of financial obligations taken on at the height of the euphoria phase, and an operational 'reality bath' in healthcare systems, which is rapidly closing the window on the pilot project-based business model'.Source: <a href="https://en.ilsole24ore.com/art/bubble-risk-l-e-start-ups-in-the-healthcare-sector-AIuzMid?refresh_ce=1">https://en.ilsole24ore.com/art/bubble-risk-l-e-start-ups-in-the-healthcare-sector-AIuzMid?refresh_ce=1</a>

Nelson Advisors featured in Il Sole 24 Ore, Italy’s Financial Times, leading economic and financial daily newspaper

Goldman Sachs, Morgan Stanley and J.P. Morgan are broadly aligned on 2026 as an AI driven but more selective year for healthcare and technology, with higher capital deployment, more focused M&amp;A &nbsp;and a premium on profitable, workflow‑integrated healthtech.​Shared big picture for 2026 All three see AI as a core productivity and earnings driver across sectors, with healthcare one of the main beneficiaries of full‑scale adoption and associated capex.​ The macro backdrop is framed as slower but positive growth with lower rates and more dispersion, favouring quality growth and cash‑generative platforms in healthcare and tech over speculative stories.​ Healthcare and healthtech views Goldman flags healthcare as a prime beneficiary of an innovation‑driven M&amp;A cycle into 2026, with larger, platform‑style deals in AI‑enabled revenue cycle, workflow platforms, advanced diagnostics and clinically validated digital therapeutics.​ J.P. Morgan’s healthcare technology spotlight expects AI‑enabled healthtech (ambient documentation, analytics, automation) to become the norm, with AI features commanding valuation premia as adoption rises among providers and payors.​ MedTech and services angles Morgan Stanley explicitly calls out a 2026 “healthcare revival,” overweight the sector, and is bullish on MedTech as post‑pandemic inventory and supply chain issues clear, enabling more normalised growth and renewed capital deployment.​ Across the banks, structural themes include shift to lower‑acuity and home‑based care, at‑home diagnostics and monitoring, and “plug‑and‑play” hospitals where robotics and devices integrate into modular clinical spaces.​ AI, capex and digital infrastructure Goldman expects AI capex by hyperscalers and large platforms to exceed 500 billion dollars by 2026, with an expanding universe of beneficiaries beyond core infrastructure into application‑layer and productivity tools, including healthcare IT.​ J.P. Morgan and Morgan Stanley both emphasise AI moving from experimentation to production, with use cases like imaging, predictive monitoring, scheduling and documentation driving measurable efficiency and clinical impact.​ Capital markets and M&amp;A setup Goldman’s global M&amp;A outlook and healthcare‑specific synthesis point to higher healthcare deal volumes, more transformative transactions and strategics/PE using M&amp;A to acquire AI and data capabilities rather than build them in‑house.​ Morgan Stanley highlights a K‑shaped recovery where high‑ROIC, innovation‑rich assets command premiums and MedTech uses divestitures plus focused M&amp;A in cardiovascular, neuro and other high‑growth segments to re‑rate.

Goldman Sachs, Morgan Stanley and JP Morgan’s combined Healthcare and Technology predictions for 2026

The prevailing mood at the 2026 J.P. Morgan Healthcare Conference is cautious but clearly more constructive, with renewed focus on execution, capital discipline, and selective growth/M&amp;A rather than a broad-based risk‑on rebound.​Overall tone For biotech, sentiment is described as cautious yet more positive than 2025, with capital available but highly selective and discipline around valuations and proof points.​ Across the week, investors are shifting from story-driven narratives to underwriting execution, governance, and credibility, signalling a return to capital discipline rather than momentum chasing.​ Capital, IPOs and M&amp;A Multiple JPM recaps frame 2026 as a potential comeback year for deal-making, with rebuilding M&amp;A momentum and expectations of more strategic acquisitions and roll‑ups, especially around AI and tech‑enabled services.​ The new issue window is seen as thin but open for a handful of scaled, profitable or clearly de‑risked issuers, while take‑privates and sponsor‑led deals remain an important release valve.​ Thematic “mood music” AI has moved from hype to accountability: conversations emphasise real‑world ROI, integration into core infrastructure (R&amp;D, diagnostics, rev cycle, ops) and governance, rather than generic “AI for everything” pitches.​ Policy, regulation and trust (especially around AI/ML, data, and reimbursement) are being treated as first‑order business variables, not sidebars, adding a sober, compliance‑aware tone to the optimism.​ Corporate messaging and fundamentals Mega‑ and large‑cap pharma/medtech are striking an upbeat note on medium‑term growth and launch pipelines, stressing “focus on fundamentals” and durable mid‑single‑digit to high‑single‑digit growth targets.​ Across management teams, there is more emphasis on profitability, unit economics, and operational leverage in digital health and tech‑enabled models, and less appetite for loss‑making growth stories without a credible path to cash generation.​ How it feels on the ground Commentators describe JPM 2026 as a barometer showing AI and data as mainstream, M&amp;A momentum rebuilding, and investors rewarding proven business models over blue‑sky narratives.​ A recurring takeaway is that reputation, trust, and transparency around AI and clinical value have become strategic assets, which is tempering exuberance and pushing the tone toward measured, fundamentals‑driven optimism.

What is the mood music at JP Morgan Healthcare conference 2026 this week?

The commencement of 2026 has heralded a definitive paradigmatic shift in the trajectory of consumer health technology, characterised principally by the transition from passive information retrieval to active, agentic health management. At the vanguard of this transformation is OpenAI’s aggressive expansion into the healthcare vertical, a strategy crystallised by two simultaneous, high-impact manoeuvres : the acquisition of the specialised healthcare technology startup Torch Health and the launch of the dedicated ChatGPT Health environment. On January 12, 2026, OpenAI confirmed the acquisition of Torch Health in an all-equity transaction valued between $60 Million and $100 Million. This strategic consolidation represents more than a mere talent acquisition; it signals the integration of critical infrastructure designed to solve the "context problem" in medical artificial intelligence. For nearly a decade, the promise of AI in healthcare has been stymied by the fragmentation of patient data, longitudinal records scattered across disparate electronic health record (EHR) systems, pdf lab reports, and siloed wearable metrics. The industry's inability to synthesise this fragmented data into a coherent "medical memory" has prevented Large Language Models (LLMs) from moving beyond generic medical advice to personalised health surveillance. &nbsp;&nbsp; Simultaneously, the deployment of ChatGPT Health, a privacy-segregated ecosystem within OpenAI's flagship platform, and OpenAI for Healthcare, a HIPAA-compliant enterprise suite, marks the operationalisation of this new capability. By integrating Torch’s "context engine," OpenAI aims to transition its 40 million daily health-seeking users from receiving static answers to engaging with a "personal super-assistant" capable of longitudinal reasoning. &nbsp;&nbsp; This report provides an analysis of this pivotal moment in health technology. It scrutinises the architectural necessity of Torch’s "medical memory," dissects the complex failure of the Forward Health model that spawned the Torch team and evaluates the intensifying competitive landscape involving Anthropic and legacy health IT incumbents.&nbsp; Full Report: <a href="https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health">https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health</a>Furthermore, it examines the privacy paradox introduced by the consumerisation of sensitive medical records outside the protective umbrella of HIPAA, forecasting the clinical and ethical ripple effects of this technological convergence.

The Future of ChatGPT Health

Anthropic has just launched Claude for Healthcare, a HIPAA‑ready offering aimed at providers, payers, life sciences, and consumer health applications, with a focus on safety, interoperability, and complex workflow automation. For an M&amp;A / build‑vs‑partner view, it effectively positions Claude as an “agentic copilot” across admin ops, clinical documentation, and life‑sciences workflows, and is already embedded in several scaled health players.​What Claude for Healthcare is Anthropic now offers a dedicated Claude for Healthcare stack, including configuration and resources so providers, payers, and health apps can use Claude through HIPAA‑ready products.​ The launch coincides with expanded life‑sciences tooling (e.g., connectors into scientific platforms, trial ops, regulatory workflows) under the broader Claude for Life Sciences umbrella.​ Core healthcare use cases Provider / health system side​Prior authorisation and claims: Drafting and packaging prior auth requests and appeals by pulling from records, coverage policies, and guidelines. Patient communication and triage: Sorting portal messages, flagging urgent issues, and drafting responses or routing tasks to the right team. Clinical documentation: Used by partners like Commure for ambient scribing and documentation, targeting “millions of clinician hours” saved annually.​ Payer and revenue‑cycle side​Claims appeals and utilization review: Assembling evidence from EMR, guidelines, and policies to support denials/appeals. Member communication: Explaining coverage decisions and benefits in plain language and assisting with care navigation. Life sciences and pharma applications Claude is being used by large pharma and biotech (e.g., Sanofi, AstraZeneca, Genmab) for literature review, protocol drafting, regulatory document prep, and analytics.​ Example: A Phase II Parkinson’s trial protocol was generated in about an hour instead of days, using Claude to structure and iterate on the design.​ With integrations like Benchling, Claude can draft SOPs, study protocols, consent forms, and support GxP‑compliant documentation and submissions.​ Patient‑facing and data interoperability angle A new consumer‑health push lets patients link their electronic health records (EHRs) via partners like HealthEx, then ask Claude questions about their own data (history summaries, test result explanations, pattern detection across devices, etc.).​ Anthropic has joined the U.S. CMS “Health Tech Ecosystem” pledge, positioning Claude as an interoperability layer to break data silos and support AI assistants that can navigate health data across systems.​ Technical performance and safety positioning Claude’s latest flagship (Opus 4.x) is benchmarked as strong on clinical knowledge, with reported performance at around 95% on the 2025 MRCGP exam, above mean human GP scores, underscoring its viability for complex clinical reasoning support (though not as an autonomous clinician).​ Anthropic is explicitly marketing safety as a differentiator in regulated environments, emphasising constrained use, auditable outputs, and alignment work to reduce harmful or hallucinated clinical guidance.<a href="https://claude.com/solutions/healthcare">https://claude.com/solutions/healthcare</a>

Anthropic launches Claude for Healthcare

Distressed M&amp;A is forecast to be a structural, not cyclical, feature of European HealthTech and MedTech dealmaking in 2026, driven by a convergence of regulatory capital requirements, funding market resets and operational pressures that create a clearing event for undercapitalised assets.​To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>Core drivers of distressed activityRegulatory Darwinism is the primary catalyst. Full MDR/IVDR implementation, EUDAMED mandatory go‑live (May 2026), and AI Act compliance have created capital‑intensive barriers that act as a “guillotine” for stand‑alone SMEs. Notified Body certification, clinical data generation, post‑market surveillance and data governance requirements are largely untenable for companies without deep balance sheets, forcing them into the arms of larger strategics that possess scaled regulatory infrastructure. This is explicitly framed as “compliance‑driven M&amp;A,” where acquirers target IP, customer bases and regulatory approvals from firms that cannot afford the transition costs.​Private equity liquidity pressures compound the dynamic. With ~$2.5 trillion in global dry powder and a significant backlog of 2019–2021 vintage assets requiring exit, PE sponsors face immense pressure to return capital to LPs. However, the IPO market remains selective, focusing only on assets with proven profitability and scale. Consequently, sponsors are increasingly utilising continuation funds, secondary buyouts and forced sales to drive consolidation, with 38% of European M&amp;A respondents expecting distress‑driven deals to dominate buy‑side activity. Financing difficulties and valuation gaps are cited as key deal drivers, creating a pool of forced sellers.​Operational and market stress is accelerating in specific sub‑sectors. Companies that achieved product‑market fit but failed to secure reimbursement traction or scale revenue are now facing flat or shrinking growth, making them prime targets for IP‑only or acqui‑hire transactions at compressed valuations. The combination of elevated cost of capital, investor retrenchment and regulatory overhead is creating a “funding reset” that will flush out “zombie” assets through down rounds, recapitalisations and pay‑to‑play restructurings.​Most vulnerable sub‑sectorsMedTech devices and diagnostics face the clearest distress risk. MDR/IVDR transition costs, UKCA divergence and rising quality‑system expenses (QMSR alignment, EUDAMED, sustainability rules) are squeezing smaller UK and EU manufacturers, many of which are expected to sell under pressure. Generalist CDMOs are also vulnerable, though specialists in viral vectors, ADCs and sterile injectables remain attractive.​Digital health and HealthTech platforms that built inflated cap tables during 2021–22 but lack clear reimbursement or sustainable unit economics are prime distressed targets. Investors are prioritising companies with robust clinical validation and AI integration; those without face acquisition for IP rather than revenue. Early‑stage AI companies that “moved fast and broke things” without regulatory foundations are becoming uninvestable and will exit as distressed sales.​Veterinary, dental and ophthalmology services in the UK are experiencing a “corporatisation clash” and “locum crisis,” with regulatory scrutiny (the “CMA Effect”) pushing capital toward Continental Europe where corporate ownership is lower (15–20% vs. ~60% in the UK). This is creating distressed sellers in the UK and fragmented buy‑and‑build opportunities in Southern Europe.​Buyer strategies and opportunities Strategic acquirers (Roche, Siemens Healthineers, Abbott, Medtronic, J&amp;J, Philips) are using M&amp;A to secure “compliance moats” and data sovereignty. They are targeting AI‑native platforms, robotics and digital pathology assets that can be integrated across existing portfolios, with a focus on H1 2026 to get ahead of EHDS implementation.​Private equity is deploying buy‑and‑build strategies in fragmented services (veterinary, dental, fertility) across Southern and Eastern Europe, acquiring at low multiples (6x–8x EBITDA) and integrating into pan‑European platforms that command premium exits (12x–15x EBITDA). PE is also forming club deals with corporate buyers in high‑growth verticals like mental health tech, femtech and preventive care.​US corporate venture funds are increasingly active in Europe, seeking early exposure to robotics and AI innovation before valuations reach US levels, effectively bridging the “Series B Gap” for European companies.​Deal structure and valuation implications Distressed transactions are expected to feature:Compressed valuations relative to 2021–22 peaks, with multiples stabilising around ~4.8x revenue and low‑teens EV/EBITDA by Q4 2025.​ IP‑only or acqui‑hire structures for digital health assets lacking revenue scale.​ Regulatory due diligence as a core financial assessment, with compliance profiles treated as assets or liabilities.​ Continuation funds and secondary buyouts to manage PE portfolio churn.​ Outlook 2026 is described as the year European HealthTech “grows up,” graduating from the “laboratory” phase to the “factory” phase. The winners will not be those with the most disruptive technology, but those with the strongest compliance moats, interoperable data and industrial logic. Distressed M&amp;A is the primary mechanism clearing the market of subscale, over‑funded or non‑compliant assets, making it a central pillar of European HealthTech and MedTech consolidation rather than a peripheral trend.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors featured in Il Sole 24 Ore, Italy’s Finan...

Goldman Sachs, Morgan Stanley and JP Morgan’s combined He...

What is the mood music at JP Morgan Healthcare conference...

The Future of ChatGPT Health

Anthropic launches Claude for Healthcare

Distressed M&A predicted to play a major role in European...